In 2021, the Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published. KDIGO is committed to providing the nephrology community with periodic updates, based on new developments for each disease. For patients with anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV), avacopan received regulatory approval in late 2021, leading to this KDIGO guideline update. In addition, the evidence supporting a lower-dose glucocorticoid induction regimen or even complete replacement of glucocorticoids has become stronger. Herein, an executive summary of the most important guideline changes from the AAV chapter is provided as a quick reference.

中文翻译：

---

KDIGO 2024 年 ANCA 相关血管炎管理临床实践指南执行摘要

2021 年，发布了《肾脏疾病：改善全球结局 (KDIGO) 肾小球疾病管理指南》。 KDIGO 致力于根据每种疾病的新进展为肾病学界提供定期更新。对于抗中性粒细胞胞浆抗体 (ANCA) 相关性血管炎 (AAV) 患者，avacopan 于 2021 年底获得监管部门批准，导致 KDIGO 指南更新。此外，支持低剂量糖皮质激素诱导方案甚至完全替代糖皮质激素的证据也变得更加有力。本文提供了 AAV 章节中最重要的指南变更的执行摘要作为快速参考。